ArcherDX
Biotechnology firm specializing in cancer research.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| N/A | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
| investor | €0.0 Valuation: €0.0 | round | |
* | $48.0m | Acquisition | |
| Total Funding | 000k | ||
Related Content
ArcherDX is a biotechnology company that specializes in genomic analysis for cancer research. The company provides a range of products and services designed to be accurate, personalized, and actionable for use in local laboratories.
Their core offering includes kits and software that enable researchers and clinicians to conduct targeted sequencing with greater speed and precision. These tools are used to identify known and novel fusion transcripts, which are important in cancer diagnostics. ArcherDX's platform is intended to make precision oncology more accessible.
The company serves researchers and clinicians in the oncology field. Their business model is based on the sale of these kits and software. ArcherDX was acquired by Invitae, a move that is expected to create a global leader in comprehensive cancer genetics and precision oncology.
Keywords: genomic analysis, precision oncology, molecular diagnostics, cancer research, sequencing kits, bioinformatics software, targeted sequencing, fusion transcripts, cancer genetics, liquid biopsy